205 related articles for article (PubMed ID: 24449872)
1. Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer.
Wei C; Cao Y; Yang X; Zheng Z; Guan K; Wang Q; Tai Y; Zhang Y; Ma S; Cao Y; Ge X; Xu C; Li J; Yan H; Ling Y; Song T; Zhu L; Zhang B; Xu Q; Hu C; Bian XW; He X; Zhong H
Proc Natl Acad Sci U S A; 2014 Feb; 111(5):E601-10. PubMed ID: 24449872
[TBL] [Abstract][Full Text] [Related]
2. MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.
Bobustuc GC; Smith JS; Maddipatla S; Jeudy S; Limaye A; Isley B; Caparas ML; Constantino SM; Shah N; Baker CH; Srivenugopal KS; Baidas S; Konduri SD
Mol Med; 2012 Sep; 18(1):913-29. PubMed ID: 22549111
[TBL] [Abstract][Full Text] [Related]
3. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
4. Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.
Zheng XQ; Guo JP; Yang H; Kanai M; He LL; Li YY; Koomen JM; Minton S; Gao M; Ren XB; Coppola D; Cheng JQ
Oncogene; 2014 Oct; 33(42):4985-96. PubMed ID: 24166501
[TBL] [Abstract][Full Text] [Related]
5. IKKepsilon phosphorylation of estrogen receptor alpha Ser-167 and contribution to tamoxifen resistance in breast cancer.
Guo JP; Shu SK; Esposito NN; Coppola D; Koomen JM; Cheng JQ
J Biol Chem; 2010 Feb; 285(6):3676-3684. PubMed ID: 19940156
[TBL] [Abstract][Full Text] [Related]
6. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Wen J; Li R; Lu Y; Shupnik MA
Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
[TBL] [Abstract][Full Text] [Related]
7. LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway.
Gao A; Sun T; Ma G; Cao J; Hu Q; Chen L; Wang Y; Wang Q; Sun J; Wu R; Wu Q; Zhou J; Liu L; Hu J; Dong JT; Zhu Z
Nat Commun; 2018 Oct; 9(1):4180. PubMed ID: 30301939
[TBL] [Abstract][Full Text] [Related]
8. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Gao P; Wang X; Jin Y; Hu W; Duan Y; Shi A; Du Y; Song D; Yang M; Li S; Han B; Zhao G; Zhang H; Fan Z; Miao QR
Breast Cancer Res; 2018 Sep; 20(1):112. PubMed ID: 30208932
[TBL] [Abstract][Full Text] [Related]
9. Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.
Busch S; Sims AH; Stål O; Fernö M; Landberg G
Cancer Res; 2015 Apr; 75(7):1457-69. PubMed ID: 25833830
[TBL] [Abstract][Full Text] [Related]
10. Protein Kinase A-induced tamoxifen resistance is mediated by anchoring protein AKAP13.
Bentin Toaldo C; Alexi X; Beelen K; Kok M; Hauptmann M; Jansen M; Berns E; Neefjes J; Linn S; Michalides R; Zwart W
BMC Cancer; 2015 Aug; 15():588. PubMed ID: 26272591
[TBL] [Abstract][Full Text] [Related]
11. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
Plaza-Menacho I; Morandi A; Robertson D; Pancholi S; Drury S; Dowsett M; Martin LA; Isacke CM
Oncogene; 2010 Aug; 29(33):4648-57. PubMed ID: 20531297
[TBL] [Abstract][Full Text] [Related]
12. p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells.
Zhuang T; Zhu J; Li Z; Lorent J; Zhao C; Dahlman-Wright K; Strömblad S
Oncotarget; 2015 Dec; 6(41):43853-68. PubMed ID: 26554417
[TBL] [Abstract][Full Text] [Related]
13. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; Coombes RC; Vigushin DM
Clin Cancer Res; 2004 Dec; 10(23):8094-104. PubMed ID: 15585645
[TBL] [Abstract][Full Text] [Related]
15. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
[TBL] [Abstract][Full Text] [Related]
16. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
17. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
[TBL] [Abstract][Full Text] [Related]
18. Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients.
Holm C; Rayala S; Jirström K; Stål O; Kumar R; Landberg G
J Natl Cancer Inst; 2006 May; 98(10):671-80. PubMed ID: 16705121
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of ERalpha at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERalpha phosphorylation in breast cancer progression.
Sarwar N; Kim JS; Jiang J; Peston D; Sinnett HD; Madden P; Gee JM; Nicholson RI; Lykkesfeldt AE; Shousha S; Coombes RC; Ali S
Endocr Relat Cancer; 2006 Sep; 13(3):851-61. PubMed ID: 16954434
[TBL] [Abstract][Full Text] [Related]
20. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
Perez White B; Molloy ME; Zhao H; Zhang Y; Tonetti DA
Mol Cancer; 2013 May; 12():34. PubMed ID: 23634843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
